Solution for intravenous administration: transparent colourless liquid (in ampoules on 5 ml, on 5 ampoules in plastic pallets, on 1 pallet in a cardboard pack);
Tablets: white, biconvex, with an engraving of "A/mE" on one of the parties (on 100 pieces in plastic bottles).

Active agent – a metoprolola tartrate:

1 ml of solution – 1 mg;
1 tablet – 100 mg.

Excipients:

Solution: sodium chloride, water for injections;
Tablets: lactoses monohydrate, silicon dioxide colloid anhydrous, magnesium stearate, sodium carboxymethylstarch, povidone.

Indications to use

Arterial hypertension (for a lowering of arterial pressure and reduction of risk of coronary and cardiovascular death, including sudden death);
Disturbances of a heart rhythm, including supraventricular tachycardia;
Stenocardia;
The functional disturbances of cordial activity which are followed by tachycardia.

Drug is also used:

For prevention of attacks of migraine;
As a part of complex therapy after a myocardial infarction and at a hyperthyroidism.

Contraindications

Atrioventricular block of II and III degrees;
Heart failure in a decompensation stage;
Clinically significant sinus bradycardia;
Sick sinus syndrome;
Cardiogenic shock;
The expressed disturbances of peripheric circulation;
Serious peripheral vascular diseases at threat of gangrene;
Arterial hypotension;
Hypersensitivity to the components which are a part of medicine.

Betalok do not appoint the patient: receiving long or intermittent treatment by the inotropic medicines operating on beta adrenoceptors; accepting β-adrenoblockers ((((((((((for intravenous administration); with an acute myocardial infarction; aged up to 18 years.

Care is demanded by Betalok's use at the following diseases / states:

Diabetes mellitus;
Atrioventricular block of the I degree;
Chronic obstructive pulmonary disease, including emphysema of lungs, chronic obstructive bronchitis, bronchial asthma;
Printsmetal's stenocardia;
Heavy renal failure.

Route of administration and dosage

Solution for intravenous administration
At supraventricular tachycardia usually apply Betalok in the form of solution for in/in, since 5 mg with rate of administering of 1-2 mg/min. Before achievement of therapeutic effect introduction can be repeated with a 5-minute interval. As a rule, the total dosage makes 10-15 mg, as much as possible – 20 mg.

For prevention and treatment of tachycardia, ischemia of a myocardium and pain at a myocardial infarction or suspicion on it intravenously enter 5 mg of Betalok. If necessary introduction is repeated with a 2-minute interval. The maximum dosage – 15 mg.

Tablets
Betalok in the form of tablets it is possible to accept irrespective of meal. The scheme of use is defined by indications:

Arterial hypertension: 100-200 mg a day once or in 2 receptions. If necessary increase in a dosage or Betalok's use along with other anti-hypertensive means is possible;
Stenocardia: 100-200 mg a day in 2 receptions (independently or along with other anti-anginal medicine);
Hyperthyroidism: 150-200 mg a day divided into 3-4 receptions;
Disturbances of a heart rhythm: 100-200 mg a day in 2 receptions (independently or along with other antiarrhytmic drug);
The functional disturbances of cordial activity which are followed by tachycardia: 100 mg a day are, once, desirable in the morning.

When carrying out a maintenance therapy after a myocardial infarction Betalok appoint 100 mg a day in 2 receptions (in morning and evening).

For prevention of attacks of migraine drug needs to be accepted in the morning and in the evening, a daily dosage – 100-200 mg.

Correction of a dosage is not required to people of advanced age and patients with an impaired renal function. At a heavy abnormal liver function decrease in a dosage can be required.

Experience of use of Betalok for children is limited.

Side effects

Usually Betalok is well had by patients, side effects have slight and reversible character:

Central nervous system: often – increased fatigue, headaches and dizzinesses; sometimes – a depression, nightmares, sleeplessness or the increased drowsiness, spasms, paresthesia; perhaps – uneasiness, impotence, the increased nervous irritability;
Cardiovascular system: bradycardia, cold snap of extremities, postural disturbances, heartbeat; sometimes – cardiogenic shock (at patients with an acute myocardial infarction), strengthening of symptoms of heart failure; very seldom – gangrene (at heavy disturbance of peripheric circulation);
Respiratory system: perhaps – an asthma, a bronchospasm (at patients with bronchial asthma), rhinitis;
Metabolism: perhaps – increase in body weight;
Integuments and allergic reactions: a small tortoiseshell, the increased perspiration; sometimes – an exacerbation of psoriasis, a hair loss;
Alimentary system: perhaps – nausea, diarrhea or a lock, pains in a stomach;
System of a hemopoiesis: in some cases – developing of thrombocytopenia.

Special instructions

At Betalok's use development of dizziness and the general weakness in this connection during therapy it is recommended to refrain from driving of motor transport is possible.

Analogs

Betalok's analogs are:

On active agent: Metozok, Vazokardin, Serdol, Lidalok, Egilok, Metoprolol;
On the action mechanism: Bidop, Kordanum, Atenolol, Koronal, Bisomor, Lokren, Bisokard, Bisogamma, Nebivator, Biprol, Biol, Nevotenz, Aritel, Nebilong, Binelol, Betak, Bisomor, Concor, Vero-Atenolol, Breviblok, Tirez, Nebilet, AUDE-not B.